Yes, an SSRI and an NDRI can be taken together, and the combination is common in clinical practice. The best-known example pairs an SSRI with bupropion, the only NDRI approved in the United States. Safety depends on which specific drugs are combined, the doses, and the patient's seizure and cardiovascular risk profile. This article explains the pharmacology behind that answer, the quantified risks, and the situations where combining them is unwise.
Two Mechanisms, One Synergy
An SSRI blocks the serotonin transporter (SERT), the protein that recycles serotonin back into the presynaptic neuron. Blocking SERT raises serotonin in the synaptic gap, which over weeks drives downstream changes in receptor sensitivity. An NDRI works differently: bupropion blocks the reuptake of norepinephrine and dopamine via the transporters NET and DAT. It has essentially no direct effect on serotonin.
That mechanistic separation is the pharmacological basis for combining them. One drug pushes the serotonin system; the other pushes catecholamines. The two pathways are distinct, so the combination does not simply double one signal. Instead it broadens the neurochemical footprint, which is why clinicians reach for it when an SSRI alone produces partial response.
The deeper "why" involves how each transporter behaves. SERT, NET, and DAT are proteins with different structures and distributions. Bupropion's occupancy of NET and DAT rises with dose, and its metabolite hydroxybupropion contributes substantially to NET blockade. Because the SSRI is not competing at NET or DAT, neither drug blunts the other's transporter occupancy. The result is additive neurotransmitter availability in two separate circuits rather than a collision at one target.
There is a catch that shapes everything downstream: bupropion inhibits CYP2D6, the liver enzyme that clears many SSRIs. That interaction, not the pharmacology of mood, is where most safety problems originate.
How Much Risk, in Numbers
The combination's headline risk is seizure. Bupropion lowers the seizure threshold in a dose-dependent way. Clinical data summarized in FDA labeling put seizure incidence at roughly 0.1 percent at doses up to 300 mg per day, rising to about 0.4 percent at 400 mg per day. Extended-release formulations carry lower peak concentrations and lower risk than immediate-release versions at equivalent daily doses.
Adding an SSRI complicates the picture. Several SSRIs inhibit CYP2D6 themselves, raising bupropion and hydroxybupropion levels and pushing seizure risk upward. Fluoxetine and paroxetine are potent CYP2D6 inhibitors; sertraline and fluvoxamine inhibit it moderately. Citalopram, escitalopram, and sertraline are comparatively weaker inhibitors, which is one reason they are often paired with bupropion. The exact magnitude of this interaction varies by drug and dose, and no single percentage captures it.
Serotonin syndrome risk is low with this pairing because bupropion does not act on serotonin. Estimates for serotonin syndrome across all serotonergic combinations vary widely, but the syndrome itself is rare and almost always involves two or more serotonergic agents. Bupropion's own label notes that it can rarely precipitate serotonin syndrome when combined with serotonergic drugs, but its mechanism is not direct serotonin agonism.
Cardiovascular effects matter at higher doses. Bupropion raises blood pressure and heart rate modestly; sustained-release bupropion at 300 mg daily produced average systolic increases of a few millimeters of mercury in trials, with larger jumps in a minority of patients. Combining it with an SSRI does not multiply that effect through a shared mechanism, but patients with uncontrolled hypertension warrant monitoring.
Edge Cases That Change the Answer
The combination is not equally safe for everyone. A history of seizure disorder, bulimia or anorexia nervosa, or alcohol withdrawal raises baseline seizure risk and argues strongly against bupropion at any dose. Head trauma, central nervous system tumors, and abrupt discontinuation of benzodiazepines or alcohol are additional seizure-risk multipliers in the label.
Age and hepatic function matter. Bupropion is metabolized in the liver, and moderate-to-severe cirrhosis calls for reduced dosing or avoidance. Older adults clear SSRIs more slowly and are more sensitive to hyponatremia, a rare SSRI effect that can be compounded by other medications.
Pregnancy and lactation present a genuine trade-off rather than a clean yes. SSRI data in pregnancy are extensive; bupropion data are thinner. Clinicians weigh relapse risk against medication exposure, and the decision is individualized.
One counterintuitive caveat deserves emphasis: the combination is often chosen precisely because it is safer than the alternative of maximum-dose SSRI monotherapy. Pushing an SSRI to its ceiling to chase response increases serotonergic side effects, sexual dysfunction, and discontinuation rates. Adding bupropion can achieve response at a lower SSRI dose, which is a risk-reduction move disguised as a risk-taking one.
Misconceptions Worth Retiring
The most common misconception is that "two antidepressants" automatically means "serotonin syndrome waiting to happen." That logic applies to combinations of two serotonergic drugs, such as an SSRI plus a monoamine oxidase inhibitor or an SSRI plus tramadol. An SSRI plus an NDRI is a serotonergic-plus-catecholaminergic pairing, a different category with a different risk profile.
A second misconception is that the NDRI label makes bupropion an "upper" that cancels SSRI sedation. Bupropion is not a stimulant in the amphetamine sense, and its activating effect is modest and variable. Some patients feel energized; others feel nothing or become irritable.
A third is that combining them means taking half doses of each. In practice, clinicians usually keep the SSRI at an effective dose and add bupropion at a starting dose, titrating upward based on response and tolerability. Dose strategy is individualized and outside the scope of general guidance.
Finally, people assume the combination treats anxiety as well as depression. Bupropion can worsen anxiety and insomnia in some patients, so an SSRI plus bupropion is not a universal anxiety strategy.
Practical Actions and Red Flags
Before and during combination therapy, these steps and thresholds matter:
Confirm there is no seizure history, eating disorder, or alcohol withdrawal, all of which are label contraindications for bupropion. Verify liver function if cirrhosis is suspected. Ask the prescriber which SSRI is being paired and why. Potent CYP2D6 inhibitors like fluoxetine and paroxetine raise bupropion levels more than citalopram or escitalopram. Check blood pressure at baseline and after dose changes. Flag a sustained rise of 10 mm Hg systolic or more, or any reading above 140/90, for review. Watch for agitation, tremor, sweating, or confusion in the first weeks, particularly if any other serotonergic drug is added. Do not stop either drug abruptly; discontinuation syndromes differ between SSRIs and bupropion. Report new insomnia, irritability, or anxiety promptly, since bupropion can unmask these.
Red-flag warnings that warrant urgent contact with a clinician:
A seizure, even a brief one. Fever with muscle rigidity, rapid heart rate, or confusion, which can signal serotonin syndrome. New chest pain or a blood pressure reading above 180/120. Severe headache, vision changes, or agitation after a dose increase. Suicidal thoughts or worsening depression, especially early in treatment or after dose changes.
Comparing the Alternatives
| Strategy | Serotonin effect | Catecholamine effect | Key risk | CYP2D6 interaction |
|---|---|---|---|---|
| SSRI alone | High | Low | Sexual dysfunction, hyponatremia | Varies by SSRI |
| NDRI (bupropion) alone | Minimal | Moderate | Seizure, blood pressure | Inhibits CYP2D6 |
| SSRI + NDRI | High | Moderate | Seizure, blood pressure, CYP2D6 elevation | Additive inhibition |
| SSRI + mirtazapine | High | Indirect | Sedation, weight gain | Low |
| SNRI alone | High | High | Blood pressure, discontinuation | Low |
| Bupropion + naltrexone | Minimal | Moderate | Seizure, nausea | Low |
The table shows the core trade-off: SSRIs plus NDRIs buy catecholamine coverage without adding serotonergic load, at the cost of seizure risk and a metabolic interaction.
Timeline of What to Expect
| Timeframe | What happens |
|---|---|
| Day 0 | Baseline blood pressure, seizure-risk review, medication reconciliation |
| Weeks 1–2 | Bupropion titration; early activation, insomnia, or anxiety may appear |
| Weeks 2–4 | SSRI effects begin building; CYP2D6 interactions stabilize |
| Weeks 4–6 | Full antidepressant response window; reassess BP and side effects |
| Weeks 6–8 | Decision point: optimize, switch, or augment further |
| Months 3+ | Maintenance; periodic BP checks and review of need |
Where the Evidence Stops
The combination of an SSRI and bupropion is well established in practice but less well studied in large randomized trials than either drug alone. Much of the support comes from augmentation studies, meta-analyses of treatment-resistant depression, and decades of prescribing data rather than head-to-head combination trials. That means the precise size of benefit and the exact added risk in a given patient are estimates, not certainties.
Equally important, most safety data describe bupropion specifically. "NDRI" is a class of one in the US market; other agents with NDRI-like profiles are not interchangeable, and their interaction profiles differ. Generalizing the bupropion evidence to any future NDRI would be a mistake.
Finally, no article can substitute for an individualized risk assessment. The answer to whether you can take them together is yes, often, with conditions. The conditions are the seizure threshold, the liver enzyme interaction, and the patient's cardiovascular and psychiatric history. A clinician who knows those details can give a safer answer than any general rule.